NASDAQ:AEGR AEGR (AEGR) Stock Price, News & Analysis → Breaking News: Elon Musk Invents New Type of A.I. (Shocking) (From InvestorPlace) (Ad) Free AEGR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$1.97▼$1.9750-Day Range$1.97▼$1.9752-Week Range$1.23▼$10.85VolumeN/AAverage Volume635,262 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get AEGR alerts: Email Address Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. About AEGR Stock (NASDAQ:AEGR)Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the development and commercialization of therapies for patients with debilitating rare diseases. It operates through pharmaceuticals segment. Its products include lomitapide and metreleptin. Lomitapide is a small molecule microsomal triglyceride transfer protein (MTP) inhibitor. Lomitapide received marketing approval under the brand name Juxtapid (lomitapide) capsules from the United States Food and Drug Administration (FDA) as an adjunct to a low-fat diet and other lipid-lowering treatments. It also received marketing authorization for lomitapide in the European Union (EU) under the brand name LOJUXTA (lomitapide) hard capsules (LOJUXTA) as a treatment for HoFH in adults. Metreleptin is a recombinant human leptin analog that exerts its function by binding to and activating the human leptin receptor. Metreleptin is marketed in the United States under the brand name MYALEPT (metreleptin) for injection (MYALEPT).Read More Ad True Market Insidersget a piece of the profit from this land This isn’t the prettiest land on earth. But it might be the most valuable. And you don’t have to own, lease, or rent any land.Click here to see my #1 investment for 2024. AEGR Stock News HeadlinesMarch 6, 2024 | uk.investing.comFTSE 100 climbs, Spring Budget income tax cut back in questionAugust 21, 2023 | thestreet.comWhy Aegerion Pharmaceuticals (AEGR) Stock Is Down TodayMay 2, 2023 | msn.comHow to Add Gmail Accounts to the Outlook App on WindowsApril 23, 2023 | msn.comNPP elects Ernest Anim to contest Kumawu by-electionApril 7, 2023 | msn.comUzbekistan adopting landmark legislation on gender-based violenceMarch 14, 2023 | msn.comBill that could impact electric vehicle sales in Mississippi is due from Governor TuesdayJanuary 21, 2023 | msn.comTalks and Visits with Draft-Eligible Players Begin for BearsDecember 22, 2022 | msn.comJadon Thompson Signs With Louisville FootballDecember 11, 2022 | msn.com'We put it in the air': Jaguars respond to last week's embarrassment with win over TitansNovember 16, 2022 | msn.comPortsmouth boss Danny Cowley identifies area that he would like to strengthen ahead of JanuaryNovember 16, 2022 | msn.comChinese customs intercept previously unknown species of cockroachOctober 31, 2022 | msn.comMissing Florida boy, who was spotted in Maine, found in CanadaOctober 20, 2022 | msn.comNew Study Finds Rich Boomers Are Stressed About Handing Down Fortunes To Their KidsAugust 28, 2022 | msn.comThorpe Park's Oktoberfest to return with beer steins, bratwursts and Bavarian beatsAugust 18, 2022 | nasdaq.comBullish Two Hundred Day Moving Average Cross - PKGAugust 12, 2022 | msn.comLancashire Teaching Hospitals Trust cares for 119 Covid-19 patients in hospitalJuly 7, 2022 | nasdaq.comNotable ETF Outflow Detected - IVV, GOOG, JNJ, NVDAJanuary 28, 2022 | thestreet.comAegerion Stock May See a Resurgence After Hitting Bottom From Ongoing ControveriesJanuary 23, 2022 | thestreet.comCramer's 'Mad Money' Recap: Next Week's Game PlanAugust 28, 2021 | news.yahoo.comLawrence switches 3 schools to virtual as COVID cases spikeAugust 28, 2021 | dailymail.co.ukOlivia Rodrigo credits Paramore for inspiring her track Good 4 U with 2007's Misery BusinessAugust 27, 2021 | msn.comFederal judge excoriates Trump lawyers, refers them for disbarmentAugust 17, 2021 | businesswire.comPapyrus Therapeutics Inc. Announces Additions to Its Board of Directors - Business WireAugust 10, 2021 | benzinga.comUnusual Options Activity Insight: GrafTech InternationalAugust 2, 2021 | reuters.comFledgling Peru govt seeks "new deal" with miners - ministerSee More Headlines Receive AEGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AEGR and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2016Today5/18/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorN/A Industry N/A Sub-IndustryBiotechnology Current SymbolNASDAQ:AEGR CUSIP00767E10 CIK1338042 Webwww.aegerion.com Phone+1-617-5007867FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report AEGR Stock Analysis - Frequently Asked Questions How were AEGR's earnings last quarter? AEGR (NASDAQ:AEGR) posted its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($1.72) EPS for the quarter, missing analysts' consensus estimates of ($0.58) by $1.14. The biopharmaceutical company earned $35.70 million during the quarter, compared to analysts' expectations of $43 million. AEGR's revenue for the quarter was down 39.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.55) earnings per share. What other stocks do shareholders of AEGR own? Based on aggregate information from My MarketBeat watchlists, some companies that other AEGR investors own include Allergan (AGN), BioMarin Pharmaceutical (BMRN), Netflix (NFLX), Tesla (TSLA), Ariad Pharmaceuticals (ARIA), Arrowhead Pharmaceuticals (ARWR), Chesapeake Energy (CHKAQ), Chipotle Mexican Grill (CMG) and Gilead Sciences (GILD). This page (NASDAQ:AEGR) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaWhat’s Really Next for America…Porter & CompanyHe called Apple at $1.49 and now he says: “Buy these 6 AI stocks.”InvestorPlaceProtect Your Bank Account Before It’s Too LateWeiss RatingsUrgent Nvidia WarningAltimetryClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEGR Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
